DZD6008 + sunvozertinib

This agent is an **experimental combination of two small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors**—DZD6008 and sunvozertinib—intended for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations, particularly in contexts of acquired resistance to previous EGFR TKI therapies and central nervous system involvement. DZD6008 is a fourth-generation, highly selective EGFR TKI with full blood-brain barrier penetration, designed to overcome resistance mutations including those that emerge after third-generation EGFR TKI failure. Sunvozertinib is an irreversible and selective EGFR inhibitor with activity against EGFR exon 20 insertion mutations, as well as other EGFR mutations (e.g., T790M), now approved in the US under the trade name Zegfrovy for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations[1][2][3][5][7]. Both agents are designed to inhibit aberrant signalling of EGFR, a pathway frequently dysregulated in NSCLC, and suppress tumor growth in both in vitro and in vivo models[1][2][7].